Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.
Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Am J Transplant. 2017 Nov;17(11):2911-2921. doi: 10.1111/ajt.14310. Epub 2017 May 30.
Solid organ transplant recipients have an elevated incidence of thyroid cancer. We evaluated a wide range of potential risk factors in a cohort of 229 300 U.S. solid organ transplant recipients linked with 15 stage/regional cancer registries (1987-2012). Incidence rate ratios (IRRs) were adjusted for age, sex, race/ethnicity, transplanted organ, year of transplantation, and time since transplantation. Hazard ratios (HRs) for death and/or graft failure were adjusted for age, sex, race/ethnicity, transplanted organ, and year of transplantation. After transplantation, 356 thyroid cancers were diagnosed. Thyroid cancer incidence was 2.50-fold higher in transplant recipients than the general population (95% confidence interval [CI] 2.25-2.77). Among recipients of different organs, kidney recipients had the highest incidence of thyroid cancer (IRR = 1.26, 95% CI 1.03-1.53). Elevated thyroid cancer incidence was associated with cholestatic liver disease/cirrhosis as an indication for liver transplantation (IRR = 1.69, 95% CI 1.09-2.63), hypertensive nephrosclerosis as an indication for kidney transplantation (IRR = 1.41, 95% CI 1.03-1.94), and longer prior dialysis among kidney recipients (5+ vs. <1 year, IRR = 1.92, 95% CI 1.32-2.80; p-trend <0.01). Posttransplantation diagnosis of thyroid cancer was associated with modestly increased risk of death (HR = 1.33, 95% CI 1.02-1.73). Overall, our results suggest that end-stage organ disease and longer duration of dialysis may contribute to higher thyroid cancer incidence in transplant recipients.
实体器官移植受者的甲状腺癌发病率升高。我们在一个由 229300 名美国实体器官移植受者组成的队列中评估了广泛的潜在危险因素,这些受者与 15 个分期/区域性癌症登记处相关联(1987-2012 年)。发病率比(IRR)通过年龄、性别、种族/族裔、移植器官、移植年份和移植后时间进行调整。死亡和/或移植物衰竭的风险比(HR)通过年龄、性别、种族/族裔、移植器官和移植年份进行调整。移植后,诊断出 356 例甲状腺癌。与普通人群相比,移植受者的甲状腺癌发病率高 2.50 倍(95%置信区间[CI] 2.25-2.77)。在不同器官的受者中,肾移植受者的甲状腺癌发病率最高(IRR=1.26,95%CI 1.03-1.53)。甲状腺癌发病率升高与作为肝移植适应证的胆汁淤积性肝病/肝硬化(IRR=1.69,95%CI 1.09-2.63)、作为肾移植适应证的高血压性肾硬化症(IRR=1.41,95%CI 1.03-1.94)和肾移植受者更长的前期透析时间相关(5+ vs. <1 年,IRR=1.92,95%CI 1.32-2.80;p-趋势<0.01)。移植后诊断出甲状腺癌与死亡风险适度增加相关(HR=1.33,95%CI 1.02-1.73)。总体而言,我们的结果表明,终末期器官疾病和更长时间的透析可能导致移植受者的甲状腺癌发病率升高。